The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

The president said he would first install a “small tariff” on pharmaceutical goods before ratcheting up the rate over the ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...

Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

Extend transfection complex formation time by up to 3 hours, reduce complex volume by >50% and maintain high titers and full ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...